Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands.
Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands; Foundation Hubrecht Organoid Technology (HUB), Utrecht, Utrecht 3584CM, the Netherlands; Cancer Genomics.nl, Utrecht, Utrecht 3584 CG, the Netherlands.
Cell Chem Biol. 2017 Sep 21;24(9):1092-1100. doi: 10.1016/j.chembiol.2017.06.012. Epub 2017 Jul 27.
Tumor organoids are 3D cultures of cancer cells that can be derived on an individual patient basis with a high success rate. This creates opportunities to build large biobanks with relevant patient material that can be used to perform drug screens and facilitate drug development. The high take rate will also allow side-by-side comparison to evaluate the translational potential of this model system to the patient. These tumors-in-a-dish can be established for a variety of tumor types including colorectal, pancreas, stomach, prostate, and breast cancers. In this review, we highlight what is currently known about tumor organoid culture, the advantages and challenges of the model system, compare it with other pre-clinical cancer models, and evaluate its value for drug development.
肿瘤类器官是一种 3D 培养的癌细胞，可以从个体患者身上以高成功率获得。这为建立大型生物库提供了机会，这些生物库可以使用相关的患者材料进行药物筛选，并促进药物开发。高成功率还可以允许进行平行比较，以评估该模型系统对患者的转化潜力。这些类器官可以用于多种肿瘤类型，包括结直肠癌、胰腺癌、胃癌、前列腺癌和乳腺癌。在这篇综述中，我们重点介绍了目前关于肿瘤类器官培养的知识，该模型系统的优缺点，并将其与其他临床前癌症模型进行了比较，评估了其在药物开发中的价值。
